OptiBiotix Health PLC Exclusive distribution agreement
October 06 2020 - 2:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
06 October 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exclusive distribution agreement with United Italian Trading
Corporation (Pte) Ltd
Exclusive rights to CholBiome(X3) in Singapore
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skincare, announces that its wholly-owned subsidiary, ProBiotix
Health Ltd ("ProBiotix"), has entered into an exclusive
distribution agreement with United Italian Trading Corporation
(Pte) Ltd ("UITC") to distribute OptiBiotix's cholesterol reducing
product, CholBiome(X3) , in Singapore.
UITC ( https://uitc.com.sg ) is an established pharmaceutical
and medical device marketing and distribution company founded in
Singapore in 1963. UITC distributes pharmaceutical and medical
products to a wide variety of clients that include hospitals,
polyclinics, medical specialists clinics, family physician clinics,
and pharmacies. As an established marketing distribution agency,
UITC delivers complete and integrated marketing and distribution
services in the healthcare sector. Their core strength is their
ability to introduce proven innovative products into the market by
working with key opinion leaders, organising user experience
clinical trials and selling into major hospitals and clinics.
UITC has agreed to place an order for 5,000 boxes of
CholBiome(X3) for delivery by the end of 2020 and increasing annual
minimum order quantities to retain exclusivity.
This agreement is another example of the increasing number of
pharmaceutical companies commercialising CholBiome(R) products into
the high value GP, hospital and pharmacy markets.
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health
commented: "We are pleased to have signed an agreement with UITC to
distribute CholBiome(X3) in Singapore. This follows on from a
recent agreement (RNS: 28 September 2020) we signed with UITC for
SlimBiome Medical. LP(LDL) (R) containing products, like
CholBiome(X3) , which have peer-reviewed scientific publications
and clinical studies are increasingly attracting the interest of
pharmaceutical companies who commercialise products in the high
value hospital GP, and pharmaceutical markets where science and
clinical studies are valued. As the gap between drugs and
probiotics developed using more rigourous scientific and clinical
approaches narrows, we can see these so called next-generation
probiotics, increasingly being seen as mainstream treatment
options."
Dexter Fung, Deputy Managing Director at UITC, commented: "At
UITC, we are proud to partner with ProBiotix Health to introduce
CholBiome(X3) in Singapore. As cardiovascular disease remains the
number one cause of fatality in Singapore, we feel that the unique
mechanism of action of CholBiome(X3) will meet the need of
improving overall cardiovascular health safely and effectively.
This will be our main mission and objective of this collaboration.
We look forward to a long and successful partnership with ProBiotix
Health."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASESEDFEFFA
(END) Dow Jones Newswires
October 06, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Oct 2023 to Oct 2024